Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
-
GSK and Adaptimmune expand strategic immunotherapy collaboration
GSK and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement
-
Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance
Governments and industry called on to work in parallel in taking comprehensive action against drug-resistant infections
-
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.
-
GSK appoints Dr Jesse Goodman to the Board as a Non-Executive Director
Dr Jesse Goodman has been appointed to the Board of the Company as a Non-Executive Director and Scientific and Medical Expert
-
GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis
GSK announced completion of its divesting of rights to ofatumumab for auto-immune indications to Novartis Pharma following reg. approval.
-
GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets
Two transactions further strengthen HIV pipeline and outlook
-
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
GSK today announced it has received positive top-line results from the phase III programme investigating sirukumab
-
Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems
A five-year partnership to fight malaria and improve health in five countries has today been launched by Comic Relief and GSK.
-
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
GSK announced that EMA has granted marketing authorisation for Nucala® as an add-on treatment for severe refractory eosinophilic asthma
-
GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK announced that dosing has commenced in a phase III study evaluating sirukumab.
-
GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris®
-
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) in patients with systemic lupus erythematosus
-
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
-
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV ,Pfizer and Shionogi today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks
-
GSK and Merck to study immunotherapy combination as potential cancer treatment
Phase I human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda®
-
GSK profiles innovative R&D portfolio to investors
40 potential new medicines and vaccines offer opportunity to drive long-term performance and deliver new benefits to patients and consumers
-
Results announcement for the third quarter 2015
Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)
-
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
GSK today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ successfully met its primary objective
-
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
GSK announced that its losmapimod phase III study, review of data from part A,3,503 patients did not indicate efficacy against larger part B
